Estudo da Universidade de Ohio, nos Estados Unidos, indica: com a medicação, 25% das pessoas tendem a jogar mais alimentos ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market cap on ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

Continue » *Stock Advisor returns as of March 18, 2025 Neil Rozenbaum has no position in any of the stocks mentioned. The ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... And I think the answer to that is flat out no. So, we’re setting ourselves up for, I think, a potentially pretty ...

Novo Nordisk received a boost from a bullish analyst note. The company also continues to be the pacesetter in the limited market for weight-loss drugs. That gravity-defying boost was due in no ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.